Mirogabalin was superior to pregabalin and placebo in decreasing average daily pain score over 7 weeks in patients with diabetic peripheral neuropathic pain, according to a study published in the International Journal of Clinical Practice.
In this systematic review and meta-analysis of randomized controlled trials (RCTs), researchers conducted a literature review using PubMed (n=33), Cochrane Central (n=20), Scopus (n=3), and Web of Science (n=35) using keywords “mirogabalin OR mirogabalin besylate OR tarlige” and “diabetic peripheral neuropathic pain OR diabetic peripheral neuropathy OR peripheral neuropathy OR neuropathic pain.”
Studies were excluded if they were duplicate citations, review articles, animal studies, studies performed on healthy study participants, and published protocols without full text, as well as citations with irrelevant conditions. Data were extracted to include baseline characteristics, risk for bias domains, and primary outcomes (efficacy and safety). Researchers pooled dichotomous outcomes as risk ratios (RRs) with 95% CI.
The data included patients with diabetic peripheral neuropathic pain (N=1732) who had received mirogabalin (n=1057), placebo (n=534), and pregabalin (n=141). When compared with placebo, mirogabalin was associated with a significant decrease in the average daily pain score after 1 week (MD -0.18; 95% CI, -0.27 to -0.08; P =.0002); pooled studies were homogenous (P =.62). It was also associated with a significant decrease in the average daily pain score after 2 weeks (MD -0.32; 95% CI, -0.42 to -0.23, P <.00001); pooled studies were heterogeneous (P =.06).
This study was limited by the small number of studies included in the meta-analysis. RCTs chosen reviewed the effects of mirogabalin for only 7 weeks.
“To the best of our knowledge, this is the first systematic review and meta-analysis to compare different doses of mirogabalin treatment, in terms of efficacy and safety measures,” the researchers concluded.
Alyoubi RA, Alshareef AA, Aldughaither SM, et al. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: a systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(5):e13744.
This article originally appeared on Clinical Pain Advisor